KRYS Investors Have Opportunity to Join Krystal Biotech, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has announced an investigation into Krystal Biotech, Inc. (NASDAQ: KRYS) for potential securities law violations. The investigation stems from Krystal Biotech's Q3 financial results on November 2, 2026, where the company revealed delays in product data releases until 2027, contrary to earlier statements promising availability in 2026. This news led to a nearly 11% drop in Krystal's share price, prompting SBS to investigate on behalf of affected shareholders.
KRYS: VYJUVEK expands globally as key pipeline readouts approach in 2026–27
Krystal Biotech's VYJUVEK product is seeing strong demand and is expected to expand globally through 2027. The company anticipates key pipeline catalysts, including the completion of NK enrollment by year-end 2027, a mid-2027 CF readout, and Hailey-Hailey data in December 2026. This information is based on an audio transcript from Krystal Biotech's Jefferies Global Healthcare Conference on November 17, 2026.
Form 4 Krystal Biotech, Inc. For: Nov 12 Filed by: ROSSI DINO A
Dino A. Rossi, a director of Krystal Biotech, Inc. (KRYS), filed a Form 4 indicating a gift of 3,500 shares of common stock to a charitable donor-advised fund on November 12, 2026. Following this transaction, Rossi beneficially owns 46,500 shares directly. The filing confirms compliance with SEC regulations regarding changes in beneficial ownership.
Krystal Biotech (KRYS), What Is Behind The Fresh Attention?
Krystal Biotech (KRYS) is gaining attention after its third-quarter earnings revealed continued profitability and a new US$400 million share repurchase authorization. Despite a recent pullback in share price, analysts view the stock as undervalued, with a fair value estimate of $392.11. However, the company's high P/E ratio of 40.3x, significantly above the industry average, suggests potential valuation risk.
Three fireside chats are scheduled for Krystal Biotech in London and Florida
Krystal Biotech (KRYS) will participate in three upcoming healthcare investor conferences, featuring fireside chats and investor meetings. The events include the Jefferies Global Healthcare Conference in London on November 17, 2026, the 9th Annual Evercore Healthcare Conference in Coral Gables on December 1, 2026, and Citi’s 2026 Global Healthcare Conference in Miami on December 2, 2026. Live webcasts and archives will be available on the company's Investors website section.
How Investors Are Reacting To Krystal Biotech (KRYS) Earnings Beat And Buyback
Krystal Biotech reported strong Q3 2026 earnings with net income of US$63.07 million and diluted EPS of US$2.05, and authorized a US$400 million share buyback. This comes as some clinical readouts are delayed to 2027, creating a tension between current cash generation from Vyjuvek and the pipeline's future. The buyback is seen as management's confidence in the company, though some analysts are more focused on the ocular DEB catalyst.
Citigroup maintains Krystal Biotech at Buy, lowers price target to $412 from $416
Citigroup has reaffirmed its "Buy" rating for Krystal Biotech but adjusted its price target slightly downward from $416 to $412, representing a 1.0% decrease. This new price target suggests a potential upside of 39.2% from the stock's closing price on November 2nd. Other analysts have also recently issued "Buy" or "Outperform" ratings for Krystal Biotech with price targets ranging from $361 to $380.
TD Cowen maintains Krystal Biotech at Buy, lowers price target to $380 from $403
TD Cowen has reiterated its "Buy" rating for Krystal Biotech (KRYS) but has lowered its price target to $380 from $403, representing a 5.7% decrease. This new price target suggests an upside of 28.4% from the stock's closing price of $295.90 on November 2. Investors can find more detailed price target data and analyst recommendations on TradingView's platform.
Krystal Biotech (KRYS) Stock Jumps As Q3 Results Put Buyback First
Krystal Biotech (KRYS) saw its stock jump 3.1% after releasing Q3 2026 results, reporting US$127.3 million in VYJUVEK revenue and US$2.05 diluted EPS. The market's positive reaction was largely attributed to the company's announcement of a US$400 million share repurchase program, signaling confidence from the profitable rare disease player. Despite a slight softening in net income and EPS compared to the previous year, Krystal Biotech demonstrated financial discipline by tightening its non-GAAP R&D and SG&A guidance.
Krystal Biotech (KRYS) Stock Looks Above Fair Value On Current Earnings
Krystal Biotech (KRYS) stock is currently trading above its fair value based on current earnings, despite a significant 7x gain over the past five years. The company's P/E ratio of 36.3x is higher than the broader biotech sector average of 19.2x, suggesting the market views it as a higher-quality operator. Analysts and community narratives present differing views on its future valuation, with some seeing undervaluation based on pipeline expansion and others considering it fairly valued due to ongoing R&D investment needs.
Krystal Biotech Releases Q3 2026 Financial Results
Krystal Biotech, Inc. (KRYS) announced its Q3 2026 financial results, reporting diluted earnings of $2.05 per share, surpassing the consensus estimate of $1.92. The company's revenue reached $127.3 million, exceeding Wall Street's forecast of $126.5 million, marking a 30.2% year-over-year increase. VYJUVEK net product revenue also saw a 30.0% year-over-year growth for the quarter.
Krystal Biotech Q3 Earnings Call Highlights
Krystal Biotech reported strong third-quarter 2026 revenue growth for its VYJUVEK treatment, reaching $127.3 million, and announced a share repurchase program of up to $400 million. The company provided updates on its pipeline, including positive initial results for its Gorlin syndrome program (KB113) and revised timelines for other clinical trials. Krystal also lowered its full-year non-GAAP R&D and SG&A expense guidance, reflecting robust financial performance and strategic capital allocation.
Is Krystal Biotech (KRYS) Fully Valued After Earnings Growth And A $400 Million Buyback?
Krystal Biotech (KRYS) has seen its share price climb significantly year-to-date and over the past year, fueled by strong earnings and a new US$400 million share repurchase program. While a common narrative suggests the stock is undervalued at $332.29 compared to a fair value of $392.11, other analyses, like a P/E ratio comparison, imply it might be trading at a premium. Investors are advised to consider both the potential rewards and risks, including pricing pressure on Vyjuvek and increased spending on late-stage programs.
Krystal Biotech Q3 2026 Earnings Call Transcript
Krystal Biotech reported strong Q3 2026 results with Vyjuvek revenue of $127.3 million, a 30% increase year-over-year, and ended the quarter with $1.2 billion in cash. The company announced a $400 million share repurchase program and highlighted significant international expansion for Vyjuvek, particularly in Germany, France, and Japan, with successful pricing negotiations in key European markets. Krystal Biotech also provided updates on its clinical pipeline, including encouraging results from the Gorlin syndrome study and progress in Hailey-Hailey disease, cystic fibrosis, and other programs, while revising full-year non-GAAP R&D and SG&A guidance downwards.
Krystal Biotech Shares Fall 3.7% Despite Q3 Earnings Beat and 30% Revenue Growth
Krystal Biotech (NASDAQ:KRYS) reported adjusted Q3 2026 earnings of $2.05 per share and revenue of $127.34 million, exceeding analyst expectations, driven by strong sales of its VYJUVEK gene therapy. Despite the positive financial results and a new $400 million share repurchase program, the company's shares declined 3.7% in pre-market trading. Krystal Biotech plans further European expansion for VYJUVEK and maintains a robust cash position of $1.2 billion.
Krystal Biotech Q3 2026 Earnings Call Is Live
Krystal Biotech's quarterly earnings call for Q3 2026 has commenced, where executives will discuss their latest financial results with Wall Street analysts. This call offers investors insights into the company's performance and potential future developments, as management commentary on demand, margins, or capital spending can significantly impact market perception.
Krystal Biotech Q3 revenue rises 30% to $127.3m
Krystal Biotech reported a 30% year-over-year increase in third-quarter VYJUVEK net revenue, reaching $127.3 million, with a 94% gross margin. Despite the revenue growth, net income declined to $63.1 million. The company authorized a $400 million share repurchase program, concluded pricing negotiations for VYJUVEK in Germany and Italy, and advanced its clinical development programs.
Krystal Biotech stock falls nearly 4% despite third quarter earnings beat
Krystal Biotech (NASDAQ:KRYS) reported strong third-quarter results, exceeding analyst expectations for both earnings per share and revenue, driven by sales of its gene therapy VYJUVEK. Despite the positive financial performance, the company's stock fell nearly 4% in pre-market trading. Krystal Biotech also announced a $400 million share repurchase program and provided fiscal year 2026 expense guidance.
Krystal Biotech, Inc. (KRYS) Tops Q3 EPS by 21c
Krystal Biotech, Inc. (NASDAQ: KRYS) announced strong third-quarter results, surpassing analyst estimates for both earnings per share (EPS) and revenue. The company reported Q3 EPS of $2.05, significantly beating the analyst consensus of $1.84 by $0.21. Revenue for the quarter also exceeded expectations, coming in at $127.34 million against an estimate of $126.77 million.
Krystal Biotech Q3 Estimates Point to 29.4% Revenue Growth
Krystal Biotech (KRYS) is projected to report a 29.4% increase in third-quarter revenue, reaching an estimated $126.54 million. However, earnings per share are expected to decline by 27.8% year over year to $1.92. The company is scheduled to release its Q3 results before U.S. markets open on Monday, November 2.
VYJUVEK Market Report Examines Industry Trends, Growth Drivers And Future Outlook
The VYJUVEK market is experiencing steady growth, driven by scientific breakthroughs in gene therapy and increasing focus on rare genetic skin conditions like dystrophic epidermolysis bullosa (DEB). Key factors include advancements in gene delivery systems, regulatory support for breakthrough treatments, and increasing investment in topical gene therapies. Krystal Biotech Inc. is a leading player, known for developing VYJUVEK, the first FDA-approved topical gel for DEB, which works by restoring functional COL7A1 gene copies.
Has The Story Under Krystal Biotech Stock Run Out?
Krystal Biotech (KRYS) stock has seen significant growth, returning 72.2% over the past year due to rising sales of its genetic medicine VYJUVEK, driven by launches in Europe and Japan. Despite some slowing growth and a pause in ex-U.S. sales due to pricing talks, the company's operating margin improved, and U.S. reimbursement approvals continue to climb. Investors are now watching Krystal's upcoming November 2026 report for further indications of VYJUVEK's revenue growth.
BlackRock reports 3.43 million Krystal Biotech (KRYS) shares in its fifth ownership amendment.
BlackRock has filed its fifth amended beneficial-ownership report for Krystal Biotech, Inc. (KRYS), indicating an 11.6% stake. As of September 30, 2026, BlackRock reported beneficial ownership of 3,427,645 common shares, with sole voting power over 3,358,055 shares and sole dispositive power over 3,427,645 shares.
Krystal Biotech | 4: Statement of changes in beneficial ownership of securities-Director Sutherland Everett Rand
This article is a formal "Statement of changes in beneficial ownership of securities" filed by Krystal Biotech. The filing specifically pertains to Director Sutherland Everett Rand, indicating a change in their beneficial ownership of the company's securities.
Krystal Biotech, Inc. Estimates – NASDAQ:KRYS
This page on TradingView provides financial estimates and actuals for Krystal Biotech, Inc. (NASDAQ: KRYS). Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates and visualizing trends over time.
3 US Biotech Stocks Investors Are Screening As China Capital Rules Tighten
New US regulations tightening capital flows into sensitive Chinese technologies are redirecting investor attention towards US-listed biotech and pharma companies focused on domestic science and funding. This article highlights three such companies: Krystal Biotech (KRYS), Iovance Biotherapeutics (IOVA), and CRISPR Therapeutics (CRSP), detailing their domestic revenue generation, innovative pipelines, and market positions as attractive options amidst the policy shift.
Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
An investment of $100 in Krystal Biotech (NASDAQ: KRYS) five years ago would now be worth $593.38, demonstrating significant outperformance against the market. The company has achieved an annualized return of 42.52% over this period, resulting in a 31.65% outperformance. This highlights the powerful impact of compounded returns on investment growth over time.
Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026
Krystal Biotech, Inc. announced that it will report its third quarter 2026 financial results on Monday, November 2, 2026, before U.S. markets open. The company will also host a conference call and webcast at 8:30 am ET on the same day to discuss the results and provide a business update. A replay of the webcast will be available for 30 days on the Investors section of Krystal Biotech's website.
HC Wainwright keeps USD 361 target for Krystal Biotech stock
HC Wainwright has reaffirmed its "Buy" rating and a USD 361.00 price target for Krystal Biotech (KRYS) stock, indicating a potential 10.84% upside from its latest Nasdaq price. The company reported a 24% year-over-year revenue increase in Q2 2026 and is expected to announce Q3 2026 results on November 2, 2026, with revenue growth anticipated but a decline in expected earnings per share.
Krystal Biotech, Inc. (KRYS) Stock forecasts
Argus has lowered its target price for Krystal Biotech, Inc. (KRYS) to $353.00, citing the company's focus on developing gene therapies for debilitating diseases within the healthcare sector. Krystal Biotech is engaged in the healthcare sector in the United States, specifically in the development of easy-to-use, redosable gene therapies. The current price of KRYS stock is $322.17.
Weekly Recap: KB113 FDA talks for Gorlin and HC Wainwright $361 target
Krystal Biotech, Inc. (KRYS) is currently in discussions with the FDA to advance its drug KB113 into later-stage trials for Gorlin syndrome. Simultaneously, HC Wainwright has reiterated a Buy rating for KRYS with a $361 target, citing the drug's positive responses in basal cell carcinoma and the company's exclusive rights to commercialize VYJUVEK for DEB. Investors are awaiting updates on the FDA alignment regarding KB113.
Insiders At Krystal Biotech Sold US$54m In Stock, Alluding To Potential Weakness
Insiders at Krystal Biotech have sold a significant amount of stock, totaling US$54 million over the past year, at an average price of US$91.43. While insider selling doesn't always indicate a problem, it suggests that insiders might view the company's shares as fully valued or overvalued. This activity raises questions about the future performance of the company's stock, particularly as the share price has increased by 14% over the last year.
Krystal Biotech stock falls 4.1 percent, 17.2 percent below high
Krystal Biotech's stock fell 4.1% on Nasdaq on October 16, 2026, closing at USD 316.58, which is 17.24% below its 52-week high. Citi recently raised its price target for the company to USD 416.00 with a Buy rating. The company is set to report its third-quarter results on November 2, 2026.
Citi Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $416
Citi has reiterated its Buy rating on Krystal Biotech (KRYS.US) and maintained its price target of $416. This indicates a continued positive outlook from the financial institution regarding the company's stock performance.
Insiders At Krystal Biotech Sold US$54m In Stock, Alluding To Potential Weakness
Krystal Biotech insiders have sold a significant amount of stock, totaling US$54 million, over the past year. This large volume of selling by multiple individuals could indicate potential concerns about the company's future performance. Despite the selling, the stock price has risen, and the company is still unprofitable.
Krystal Biotech (KRYS) Posts Strong KB113 Data, Is The Stock Fully Priced?
Krystal Biotech (KRYS) has shown strong early KB113 trial data for Gorlin syndrome, with over 80% regression in basal cell carcinoma lesions, leading to new FDA discussions. Despite a significant year-to-date share price return of 33.65%, the stock is considered 16% undervalued by many, with a fair value estimated at $392.11 per share. However, looking at the P/E ratio, KRYS trades at 40.5x earnings, higher than the fair ratio of 34x and the broader US biotech average of 17.6x, suggesting potential valuation risk.
Krystal Biotech Says KB113 Demonstrates Significant Regression in Lesions in Gorlin Syndrome Pilot Study
Krystal Biotech announced positive results from its pilot study of KB113 for Gorlin Syndrome. The study demonstrated significant regression in basal cell carcinoma lesions, indicating potential as a treatment for the condition. Further details are available to premium subscribers.
HC Wainwright & Co. reiterates Buy rating on Krystal Biotech, $361 price target
HC Wainwright & Co. has reiterated its Buy rating for Krystal Biotech (KRYS) and set a price target of $361.00, suggesting a 9.2% upside from its Oct 14 closing price. The firm highlighted strong clinical evidence from KB113 for basal cell carcinoma and valuable market potential for VYJUVEK in dystrophic epidermolysis bullosa and the orphan derm market.
HC Wainwright keeps USD 361.00 target for Krystal Biotech stock
HC Wainwright has reaffirmed a Buy rating for Krystal Biotech (KRYS) and set a price target of USD 361.00. The company is set to report its third-quarter results on November 2, 2026, with current stock prices hovering around EUR 295.80 and a market capitalization of USD 9.8 billion. Despite mixed second-quarter results, product growth and execution remain key to its valuation, while the stock trades below its yearly high.
Citigroup raises Krystal Biotech price target on Vyjuvek sales and promising KB113 trial results
Citigroup has increased its price target for Krystal Biotech to $416, up from $386. This adjustment is based on strong Q2 revenue of $119.2 million from Vyjuvek and positive early clinical data for KB113, a potential treatment for basal cell carcinomas. The company also boasts a robust financial position with $1.1 billion in cash and a 40% operating margin.
Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial
Krystal Biotech (NASDAQ: KRYS) announced promising clinical trial results for KB113, an intratumoral immunotherapy for Gorlin syndrome, a rare genetic disorder causing basal cell carcinomas. The treatment achieved over 80% lesion reduction and demonstrated an abscopal effect, causing regression in non-injected tumors. Krystal Biotech is discussing advanced clinical development with the FDA, aiming to provide a non-surgical solution for patients with this debilitating condition.
An experimental skin cancer treatment shrank some tumors doctors didn't inject. Three patients were studied.
Krystal Biotech (KRYS) reported positive results from a pilot study of its experimental skin cancer treatment, KB113, for Gorlin syndrome. The study, involving three patients, showed that over 80% of assessed basal cell carcinoma lesions regressed, including those not directly injected, suggesting an "abscopal effect." The company is now in discussions with the FDA for advanced clinical development of KB113.
Krystal Biotech reports positive early data for Gorlin syndrome trial
Krystal Biotech announced positive early data from a pilot study for KB113, its treatment for Gorlin syndrome. The study showed that over 80% of basal cell carcinoma lesions regressed in three patients, with many showing significant clinical regression, including complete responses in biopsied lesions. The company plans to discuss advanced clinical development with the U.S. FDA.
(KRYS) Movement as an Input in Quant Signal Sets
The article analyzes Krystal Biotech Inc. (NASDAQ: KRYS), noting divergent sentiment across all time horizons, which suggests choppy market conditions. It highlights an exceptional 34.6:1 risk-reward setup, targeting a 10.0% gain versus a 0.3% risk, and provides AI-generated trading strategies for different risk profiles. The analysis also includes multi-timeframe signal data indicating neutral near-term, weak mid-term, and strong long-term signals for the stock.
RBC Capital Sticks to Its Buy Rating for Krystal Biotech (KRYS)
RBC Capital analyst Lisa Walter maintained a Buy rating on Krystal Biotech (KRYS) with a price target of $400.00. This follows Goldman Sachs also resuming coverage with a Buy rating and a $441.00 price target. Krystal Biotech reported strong quarterly revenues of $119.22 million and a net profit of $54.77 million, though corporate insider sentiment on the stock is currently negative due to increased selling activity.
Krystal Biotech, Inc. (KRYS) Stock forecasts
Krystal Biotech Inc. (KRYS) is a healthcare company focused on developing gene therapies. Argus has lowered its target price for KRYS to $386.00, while the current price stands at $331.61.
Krystal Biotech (NasdaqGS:KRYS) Stock Price
This article provides an overview of Krystal Biotech's (KRYS) stock performance and analyst sentiment. It highlights the company's valuation, recent narrative updates from various analysts focusing on pipeline expansion and cost management, and key financial details. The consensus suggests the stock is undervalued, driven by its genetic medicines platform and pipeline potential.
Goldman starts coverage of Krystal Biotech stock at USD 441.00 target
Goldman Sachs initiated coverage of Krystal Biotech (KRYS) with a "Buy" rating and a USD 441.00 price target. This follows Krystal Biotech's second-quarter revenue of USD 119.22 million and diluted earnings per share of USD 1.79. The company's stock was trading at EUR 296.35 on October 8, 2026, on Lang & Schwarz, and its next earnings release is estimated for November 2, 2026.
Goldman Sachs sets USD 441 target for Krystal Biotech stock
Goldman Sachs has set a USD 441 price target for Krystal Biotech (KRYS) stock, resuming coverage with a Buy rating due to the company's commercial execution and pipeline potential, particularly with its VYJUVEK product. Despite a recent revenue shortfall, the analyst's thesis highlights the company's strong gross margin and the value of its genetic medicine pipeline. The next test for Krystal Biotech will be its third-quarter results scheduled for November 2, 2026.
$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today
An investment of $1000 in Krystal Biotech (NASDAQ: KRYS) five years ago would now be worth $6,435.47, demonstrating a significant outperformance against the market. The company has achieved an average annual return of 45.63%, leading to its current market capitalization of $9.78 billion. This highlights the substantial impact of compounded returns over time.